Genelux Corp cash flow statement

In fiscal 2025, Genelux Corp's operations generated −$25.3m of cash; it spent $1.1m on capital projects, leaving free cash flow of −$26.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Genelux Corp: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−4	−20	−21	−25
Depreciation and amortisation	1	0	0	0
Stock-based pay	2	3	6	6
Capital spending	0	1	0	1
Free cash flow	−4	−21	−22	−26
Free cash flow after stock pay	−6	−24	−27	−32
Shares issued	—	25	28	10

US$ millions unless shown otherwise. Fiscal quarters.

Genelux Corp: cash flow statement, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q1Mar 2024	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024
Cash from operations	−5	−5	−3	−7	−4	−7	−6	−4
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	0	0	1	2	1	1	2	1
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−5	−6	−4	−7	−4	−7	−6	−4
Free cash flow after stock pay	−5	−6	−4	−9	−6	−8	−8	−6
Shares issued	15	7	4	0	—	—	0	0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CELZ vs GNLX GNLX vs LYEL AIM vs GNLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Genelux Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Genelux Corp.